Please login to the form below
molnupiravir
This page shows the latest molnupiravir news and features for those working in and with pharma, biotech and healthcare.
Merck and Ridgeback’s COVID-19 pill fails to prevent infection within households
Lagevrio (molnupiravir) is already approved or authorised to treat certain adults who have been diagnosed with COVID-19 in several markets, including the US, UK and China, but is not authorised
Latest news
-
NICE publishes draft guidance recommending three COVID-19 treatments
Those not recommended at this stage are Regenerons’ casirivimab and imdevimab, Merck and Ridgeback’s molnupiravir, GSK and Vir Biotechnology’s sotrovimab, as well as Gilead's remdesivir and AstraZeneca’s ... Molnupiravir and remdesivir are not
-
Merck and Ridgeback fulfil US deal for molnupiravir
Merck &Co – known as MSD outside the US and Canada – and Ridgeback Biotherapeutics have announced that approximately 3.1 million courses of its investigational oral antiviral COVID-19 treatment, molnupiravir, have ... Alongside the most recent US
-
FDA restricts use of certain antibody treatments for COVID-19
The statement notes that while restrictions have been made on Regeneron and Lilly treatments at this time, there are still several therapy options, including Paxlovid, sotrovimab, Veklury (remdesivir) and molnupiravir, that
-
US regulators set to approve oral antiviral against COVID-19
The FDA looks set to authorise Merck’s molnupiravir after its advisory body recommended the antiviral treatment, while Pfizer’s Paxlovid may be next. ... Oral medications like molnupiravir and Paxlovid are significantly more convenient than the
-
Pfizer's oral antiviral Paxlovid significantly cuts risk of severe COVID-19
Merck’s Lagevrio (molnupiravir) -3CL protease inhibitor, approved in the UK last week, was originally developed to treat influenza.
More from news
Approximately 3 fully matching, plus 15 partially matching documents found.
Subscribe to our email news alerts
- Contagious Conversations: Exploring Infectious Disease in the Digital Age
- Austrian State Secretary to speak at FlyPharma Europe 2023
- Further data for AstraZeneca/Daichii Sankyo’s Enhertu for breast cancer requested by NICE
- Gritstone Bio receives $433m BARDA contract for COVID-19 vaccine candidate
- EDX Medical Group develops multi-disease 'point-of-care' rapid tests for cancer, infections and cardiovascular conditions
- ScreenPoint Medical to showcase AI software at European scientific meeting
No results were found
PMHub
M3 (EU)
M3 has over 20 years’ experience in building online doctor communities. M3 is the world’s largest network of verified doctors...
Latest intelligence
- The importance of accelerating clinical trial diversity
- Diversity shouldn’t be an afterthought – it’s an investment in the credibility of scientific endeavour...
- Digital Opinion Leaders: The Role of Influencers in Medical Communications
- There are many informed, knowledgeable HCPs who talk about a disease state online, but not all of them are influencers. This paper explores who digital opinion leaders are and how...
- Creating Hope Though Action – World Suicide Prevention Day
- At Mednet Group, we believe that actions speak louder than words. That's why we're getting behind this year's Suicide Prevention Day campaign of 'creating hope through action'....
